Par responds to Searle Flagyl look-alike suit
Executive Summary
Par said that the Aug. 20 New Jersey District Court decision prohibiting it from marketing a look-alike version of metronidazole "will have no effect on its operations." Par said that total sales of the Flagyl look-alike generic metronidazole "were less than $100,000." Par will continue to sell a non-look-alike version of metronidazole that has been on the market for more than two years.